Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 10,670,000 shares, a decline of 11.3% from the January 15th total of 12,030,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the days-to-cover […]
Apellis Pharmaceuticals (NASDAQ:APLS) Raised to Buy at Jefferies Financial Group themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “outperform” rating reiterated by Robert W. Baird in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $81.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 21.68% from the stock’s previous close. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price boosted by stock analysts at Oppenheimer from $75.00 to $79.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 20.78% from the […]
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) gapped down before the market opened on Tuesday following insider selling activity. The stock had previously closed at $65.45, but opened at $63.81. Apellis Pharmaceuticals shares last traded at $63.90, with a volume of 195,943 shares changing hands. Specifically, CAO James George Chopas sold 864 […]